Raber M, Schulz H U, Schürer M, Bias-Imhoff U, Momberger H
Temmler Pharma GmbH, Marburg, Germany.
Arzneimittelforschung. 1999 Jul;49(7):588-93. doi: 10.1055/s-0031-1300467.
In an open, randomized four-period crossover study in 24 healthy male volunteers a newly developed tramadol (CAS 27203-92-5) sustained release capsule with and without concomitant food intake and an instant release formulation were administered. Additionally, a sustained release tablet was applied as further reference substance. Statistical analysis of AUC(0-infinity) and Cmax after logarithmic transformation yielded bioequivalence of tramadol sustained release capsules with and without concomitant food intake. Therefore, lack of food interaction could be concluded. The investigation also showed an only slightly diminished bioavailability of the tramadol sustained release capsules compared to the instant release formulation. Furthermore, the sustained release capsules investigated showed enhanced retardation at almost identical bioavailability compared with the sustained release competitor drug.
在一项针对24名健康男性志愿者的开放性、随机四周期交叉研究中,给予一种新开发的曲马多(化学物质登记号27203-92-5)缓释胶囊,分别在有或无食物摄入的情况下服用,同时还给予了速释制剂。此外,还使用了一种缓释片作为进一步的参比物质。对对数转换后的AUC(0-无穷大)和Cmax进行统计分析,结果表明,有或无食物摄入时曲马多缓释胶囊具有生物等效性。因此,可以得出不存在食物相互作用的结论。该研究还表明,与速释制剂相比,曲马多缓释胶囊的生物利用度仅略有降低。此外,与缓释参比药物相比,所研究的缓释胶囊在生物利用度几乎相同的情况下显示出更强的缓释效果。